{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T21:59:50Z","timestamp":1720216790780},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Aim\u2002Whole-body bone scan (BS) is the clinical standard in detecting bone metastases in prostate cancer patients. Additional SPECT\/CT has allowed to significantly increase its diagnostic accuracy. However, performing both planar and additional SPECT\/CT prolongs the total examination time and lowers patient throughput. In this study we aim to assess the diagnostic performance of a SPECT\/CT-only protocol compared to the traditional procedure that is BS with a facultative SPECT\/CT in case of unclear findings.<\/jats:p><jats:p>\n          Methods\u200250 patients with high-risk prostate cancer and suspected bone metastases were enrolled in this retrospective study. All patients received a whole-body Tc-99m-DPD BS followed by a 3 field-of-view (FOV) SPECT\/CT (GE Discovery 670 Pro\u00ae) covering an area from the vertex to the mid-femur. Metastatic lesions were evaluated visually on BS and SPECT\/CT and correlated to PSA-levels.<\/jats:p><jats:p>\n          Results\u2002Detection rate was up to 50\u200a% higher in SPECT\/CT than in BS (n\u200a=\u200a2829 vs. n\u200a=\u200a1942; p\u200a&lt;\u200a0.001), but 31\/1942 (1.5\u200a%) lesions detected on BS were located out of the SPECT\/CT field-of-view. In our analysis a PSA-level of &gt;\u200a80\u200a\u00b5g\/l could be defined as a cut-off-value for metastatic spread beyond mid-thigh, as no patient with PSA&lt;\u200a80\u200a\u00b5g\/l had localizations outside the SPECT\/CT field-of-view (AUCPSA\u200a=\u200a0.95, p\u200a&lt;\u200a0.001 sensitivity: 100\u200a%, specificity: 77\u200a%, NPV: 100\u200a%, PPV: 67\u200a%). The SPECT\/CT-only protocol did not prolong acquisition time significantly as compared to BS.<\/jats:p><jats:p>\n          Conclusions\u2002In patients with high-risk prostate cancer presenting with PSA &lt;\u200a80\u200a\u00b5g\/l and absent clinical symptoms, vertex to mid-thighs 3-FOV-SPECT\/CT was representative for the entire skeletal system and was able to detect more lesions than planar acquisition. This procedure did not prolong patient handling time significantly.<\/jats:p>","DOI":"10.1055\/a-1022-4115","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:01:17Z","timestamp":1573516877000},"page":"451-459","source":"Crossref","is-referenced-by-count":1,"title":["Transitioning to whole-body SPECT\/CT in prostate cancer staging: a\u00a0new concept for a better imaging workflow"],"prefix":"10.1055","volume":"58","clinical-trial-number":[{"clinical-trial-number":"drks00013571","registry":"10.18810\/drks"}],"author":[{"given":"Matthias","family":"Weissinger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University-Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Kupferschl\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University-Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"La Foug\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University-Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Dittmann","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University-Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Fiz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Clinical Molecular Imaging, University-Hospital T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Internal Medicine, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,11,11]]},"container-title":["Nuklearmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1022-4115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T14:26:37Z","timestamp":1576851997000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1022-4115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":0,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2019,12,3]]},"published-print":{"date-parts":[[2019,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1022-4115","relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]}}}